Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brian G Feagan

Showing results (321-330 of 464) with videos related to

Pageof 47
Sort By:
The Lancet. Gastroenterology & Hepatology|November 16, 2025
Safety and pharmacokinetics of SOR102, an oral bispecific inhibitor of TNF and interleukin-23 in healthy participants and patients with ulcerative colitis: a first-in-human, double-blind, randomised, placebo-controlled, phase 1 trialVipul Jairath, Silvio Danese, Geert R D'Haens, et al.
Gastroenterology|June 6, 2013
Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitisWilliam J Sandborn, Brian G Feagan, Colleen Marano, et al.
Journal of Crohn'S & Colitis|October 6, 2017
Effect of Adalimumab on Clinical Outcomes and Health-related Quality of Life Among Patients With Ulcerative Colitis in a Clinical Practice Setting: Results From InspirADASimon Travis, Brian G Feagan, Laurent Peyrin-Biroulet, et al.
Inflammatory Bowel Diseases|April 25, 2024
Reliability and Responsiveness of Clinical and Endoscopic Outcome Measures in Crohn's DiseaseReena Khanna, Brian G Feagan, Guangyong Zou, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|September 24, 2023
Vedolizumab, Adalimumab, and Methotrexate Combination Therapy in Crohn's Disease (EXPLORER)Jean-Frederic Colombel, Ryan C Ungaro, Bruce E Sands, et al.
JAMA Network Open|April 18, 2024
Incidence of Total Knee Arthroplasty After Arthroscopic Surgery for Knee Osteoarthritis: A Secondary Analysis of a Randomized Clinical TrialTrevor B Birmingham, Codie A Primeau, Salimah Z Shariff, et al.
The American Journal of Gastroenterology|January 30, 2019
Histologic Healing Rates of Medical Therapies for Ulcerative Colitis: A Systematic Review and Meta-Analysis of Randomized Controlled TrialsRobert Battat, Marjolijn Duijvestein, Leonardo Guizzetti, et al.
Gastroenterology|November 26, 2018
Efficacy and Safety of Abrilumab in a Randomized, Placebo-Controlled Trial for Moderate-to-Severe Ulcerative ColitisWilliam J Sandborn, Marcoli Cyrille, Mark Berner Hansen, et al.
Journal of Crohn'S & Colitis|March 24, 2017
Exposure-efficacy Relationships for Vedolizumab Induction Therapy in Patients with Ulcerative Colitis or Crohn's DiseaseMaria Rosario, Jonathan L French, Nathanael L Dirks, et al.
Journal of Crohn'S & Colitis|February 1, 2018
Corrigendum: Exposure-efficacy Relationships for Vedolizumab Induction Therapy in Patients with Ulcerative Colitis or Crohn's DiseaseMaria Rosario, Jonathan L French, Nathanael L Dirks, et al.
Pageof 47

Showing results (321-330 of 464) with videos related to

Sort By:
Pageof 47
The Lancet. Gastroenterology & Hepatology|November 16, 2025
Safety and pharmacokinetics of SOR102, an oral bispecific inhibitor of TNF and interleukin-23 in healthy participants and patients with ulcerative colitis: a first-in-human, double-blind, randomised, placebo-controlled, phase 1 trialVipul Jairath, Silvio Danese, Geert R D'Haens, et al.
Gastroenterology|June 6, 2013
Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitisWilliam J Sandborn, Brian G Feagan, Colleen Marano, et al.
Journal of Crohn'S & Colitis|October 6, 2017
Effect of Adalimumab on Clinical Outcomes and Health-related Quality of Life Among Patients With Ulcerative Colitis in a Clinical Practice Setting: Results From InspirADASimon Travis, Brian G Feagan, Laurent Peyrin-Biroulet, et al.
Inflammatory Bowel Diseases|April 25, 2024
Reliability and Responsiveness of Clinical and Endoscopic Outcome Measures in Crohn's DiseaseReena Khanna, Brian G Feagan, Guangyong Zou, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|September 24, 2023
Vedolizumab, Adalimumab, and Methotrexate Combination Therapy in Crohn's Disease (EXPLORER)Jean-Frederic Colombel, Ryan C Ungaro, Bruce E Sands, et al.
JAMA Network Open|April 18, 2024
Incidence of Total Knee Arthroplasty After Arthroscopic Surgery for Knee Osteoarthritis: A Secondary Analysis of a Randomized Clinical TrialTrevor B Birmingham, Codie A Primeau, Salimah Z Shariff, et al.
The American Journal of Gastroenterology|January 30, 2019
Histologic Healing Rates of Medical Therapies for Ulcerative Colitis: A Systematic Review and Meta-Analysis of Randomized Controlled TrialsRobert Battat, Marjolijn Duijvestein, Leonardo Guizzetti, et al.
Gastroenterology|November 26, 2018
Efficacy and Safety of Abrilumab in a Randomized, Placebo-Controlled Trial for Moderate-to-Severe Ulcerative ColitisWilliam J Sandborn, Marcoli Cyrille, Mark Berner Hansen, et al.
Journal of Crohn'S & Colitis|March 24, 2017
Exposure-efficacy Relationships for Vedolizumab Induction Therapy in Patients with Ulcerative Colitis or Crohn's DiseaseMaria Rosario, Jonathan L French, Nathanael L Dirks, et al.
Journal of Crohn'S & Colitis|February 1, 2018
Corrigendum: Exposure-efficacy Relationships for Vedolizumab Induction Therapy in Patients with Ulcerative Colitis or Crohn's DiseaseMaria Rosario, Jonathan L French, Nathanael L Dirks, et al.
Pageof 47